Table 2.
Comparison of CR in Subgroups Divided by Demographic and Clinical Characteristics
| Parameters | N | Not CR | CR | p Value |
|---|---|---|---|---|
| Age | 0.091 | |||
| ≥65 years | 121 | 103 (85.1) | 18 (14.9) | |
| <65 years | 246 | 191 (77.6) | 55 (22.4) | |
| Gender | 0.506 | |||
| Male | 286 | 227 (79.4) | 59 (20.6) | |
| Female | 81 | 67 (82.7) | 14 (17.3) | |
| History of HB | 0.001 | |||
| Yes | 244 | 184 (75.4) | 60 (24.6) | |
| No | 123 | 110 (89.4) | 13 (10.6) | |
| History of HC | 0.995 | |||
| Yes | 5 | 4 (80.0) | 1 (20.0) | |
| No | 362 | 290 (80.1) | 72 (19.9) | |
| History of drink | 0.496 | |||
| Yes | 153 | 120 (78.4) | 33 (21.6) | |
| No | 214 | 174 (81.3) | 40 (18.7) | |
| History of cirrhosis | 0.795 | |||
| Yes | 176 | 140 (79.5) | 36 (20.5) | |
| No | 191 | 154 (80.6) | 37 (19.4) | |
| Histology | 0.037 | |||
| Primary HCC | 275 | 212 (77.1) | 63 (22.9) | |
| Primary ICC | 37 | 34 (91.9) | 3 (8.1) | |
| Secondary liver cancer | 55 | 48 (87.3) | 7 (12.7) | |
| Tumor distribution | 0.008 | |||
| Multifocal | 244 | 205 (84.0) | 39 (16.0) | |
| Unifocal | 123 | 89 (72.4) | 34 (27.6) | |
| Tumor location | 0.052 | |||
| Left liver | 56 | 41 (73.2) | 15 (26.8) | |
| Right liver | 183 | 142 (77.6) | 41 (22.4) | |
| Bilobar | 128 | 111 (86.7) | 17 (13.3) | |
| Largest nodule size | 0.002 | |||
| ≥5 cm | 184 | 159 (86.4) | 25 (13.6) | |
| <5 cm | 183 | 135 (73.8) | 48 (26.2) | |
| Portal vein invasion | <0.001 | |||
| Yes | 103 | 95 (92.2) | 8 (7.8) | |
| No | 264 | 199 (75.4) | 65 (24.6) | |
| Hepatic vein invasion | 0.078 | |||
| Yes | 48 | 43 (89.6) | 5 (10.4) | |
| No | 319 | 251 (78.7) | 68 (21.3) | |
| ECOG performance status | 0.058 | |||
| 0 | 200 | 153 (76.5) | 47 (23.5) | |
| 1 | 127 | 103 (81.1) | 24 (18.9) | |
| 2 | 30 | 28 (93.3) | 2 (6.7) | |
| 3 | 10 | 10 (100.0) | 0 (0.0) | |
| Child–Pugh Stage | 0.314 | |||
| A | 261 | 203 (77.8) | 58 (22.2) | |
| B | 49 | 41 (83.7) | 8 (16.3) | |
| C | 2 | 2 (100.0) | 0 (0.0) | |
| BCLC Stage | 0.021 | |||
| 0 | 1 | 1 (100.0) | 0 (0.0) | |
| A | 76 | 50 (65.8) | 26 (34.2) | |
| B | 119 | 98 (82.4) | 21 (17.6) | |
| C | 115 | 96 (83.5) | 19 (16.5) | |
| D | 1 | 1 (100.0) | 0 (0.0) | |
| Cycles of DEB-TACE treatment | 0.908 | |||
| 1 cycle | 305 | 244 (80.0) | 61 (20.0) | |
| 2 or more cycles | 62 | 50 (80.6) | 12 (19.4) | |
| Previous cTACE treatment | 0.491 | |||
| Yes | 138 | 108 (78.3) | 30 (21.7) | |
| No | 229 | 186 (81.2) | 43 (18.8) | |
| Previous surgery | 0.845 | |||
| Yes | 109 | 88 (80.7) | 21 (19.3) | |
| No | 258 | 206 (79.8) | 52 (20.2) | |
| Previous systematic chemotherapy | 0.396 | |||
| Yes | 46 | 39 (84.8) | 7 (15.2) | |
| No | 321 | 255 (79.4) | 66 (20.6) | |
| Previous radiofrequency ablation | 0.091 | |||
| Yes | 53 | 47 (88.7) | 6 (11.3) | |
| No | 314 | 247 (78.7) | 67 (21.3) | |
| Previous targeted therapy | 0.776 | |||
| Yes | 12 | 10 (83.3) | 2 (16.7) | |
| No | 355 | 284 (80.0) | 71 (20.0) | |
| DEBs size | 0.262 | |||
| 100–300 μm | 354 | 282 (79.7) | 72 (20.3) | |
| 300–500 μm | 13 | 12 (92.3) | 1 (7.7) | |
| Drug dosage | 0.427 | |||
| Low dose | 34 | 29 (85.3) | 5 (14.7) | |
| Normal dose | 333 | 265 (79.6) | 68 (20.4) | |
| Combination of ordinary embolization agent | 0.252 | |||
| Yes | 116 | 97 (83.6) | 19 (16.4) | |
| No | 251 | 197 (78.5) | 54 (21.5) |
Data are presented as count with percentage in parentheses. Comparison between two groups was determined by chi-square test. A value of p < 0.05 was considered significant (bold). CR, complete response.